New study tracks Real-World safety of hair loss drug litfulo
NCT ID NCT06279221
First seen Mar 07, 2026 · Last updated May 17, 2026 · Updated 7 times
Summary
This study follows 487 adults with alopecia areata who are starting Litfulo (ritlecitinib) for the first time. Researchers will monitor side effects and measure hair regrowth using the SALT score, aiming for a score of 20 or less (meaning 80% or more scalp hair coverage). The goal is to confirm the drug's safety and effectiveness in everyday use, not just in controlled trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALOPECIA AREATA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.